MacroGenics (MGNX) Metrics: History & Chart

MacroGenics, Inc.(MGNX)

Biotechnology · Rockville, MD

$3.71-0.06 (-1.72%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

About MacroGenics, Inc.

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Rockville, MD

293 employees

www.macrogenics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eric Risser

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-7.14%
30D Total Return	-14.32%
YTD Total Return	+134.16%
1Y Total Return	+111.80%
3Y Total Return	-21.14%
5Y Total Return	-81.20%
10Y Total Return	-87.46%
15Y Total Return	N/A
20Y Total Return	N/A

2026	+134.16%
2025	-50.46%
2024	-66.22%
2023	+43.37%
2022	-58.19%
2021	-29.79%
2020

CAGR TTM	+111.04%
CAGR 3Y	-7.61%
CAGR 5Y	-28.42%
CAGR 10Y	-18.75%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	25.96
PE Ratio Avg TTM	28.08
PE Ratio Avg 3Y	28.08
Current VS TTM Avg	-7.54%
Current VS 3Y Avg	-7.54%
Current VS 5Y Avg	-7.54%

All Metrics

MGNX Valuation Metrics

MGNX Stock Price Metrics

MGNX Dividend Metrics

MGNX Growth Rate Metrics

MGNX Discounted Cash Flow Metrics

MGNX Returns By Period

MGNX Yearly Returns

MGNX Average Annual Returns By Period (CAGR)

MGNX Revenue Metrics

MGNX PE Ratio Metrics

MGNX PS Ratio Metrics

MGNX PB Ratio Metrics

MGNX Price to Free Cash Flow Ratio Metrics

MGNX Debt to Equity Ratio Metrics

MGNX PEG Ratio Metrics

MGNX FCF Yield

MGNX Earnings Yield

MGNX EBITDA Yield

MGNX OCF Yield

MGNX EV/EBIT Ratio Metrics

MGNX EV/EBITDA Ratio Metrics

MGNX EV/Assets Ratio Metrics

MGNX EV/Sales Ratio Metrics

MGNX Current Ratio Metrics

MGNX Quick Ratio Metrics

MGNX ROIC Metrics

MGNX Return on Assets Metrics

MGNX Return on Equity Metrics

MGNX Net Profit Margin Metrics

MGNX Gross Profit Margin Metrics

MGNX Tax Rate Metrics

PS Ratio	1.43
PS Ratio Avg TTM	1.23
PS Ratio Avg 3Y	2.56
Current VS TTM Avg	+16.54%
Current VS 3Y Avg	-44.05%
Current VS 5Y Avg	-57.40%

PB Ratio	5.59
PB Ratio Avg TTM	5.47
PB Ratio Avg 3Y	2.82
Current VS TTM Avg	+2.27%
Current VS 3Y Avg	+98.02%
Current VS 5Y Avg	+117.35%

PFCF Ratio	108.07
PFCF Ratio Avg TTM	98.50
PFCF Ratio Avg 3Y	98.50
Current VS TTM Avg	+9.71%
Current VS 3Y Avg	+9.71%
Current VS 5Y Avg	+9.71%

Debt/Equity Ratio	0.82
Debt/Equity Ratio Avg TTM	1.46
Debt/Equity Ratio Avg 3Y	0.40
Current VS TTM Avg	-44.09%
Current VS 3Y Avg	+106.74%
Current VS 5Y Avg	+178.88%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	0.93%
FCF Yield Avg TTM	1.02%
FCF Yield Avg 3Y	1.02%
Current VS TTM Avg	-8.38%
Current VS 3Y Avg	-8.38%
Current VS 5Y Avg	-8.38%

Earnings Yield	3.85%
Earnings Yield Avg TTM	5.21%
Earnings Yield Avg 3Y	5.21%
Current VS TTM Avg	-26.12%
Current VS 3Y Avg	-26.12%
Current VS 5Y Avg	-26.12%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	840.23
Ev/Ebit Ratio Avg TTM	378.61
Ev/Ebit Ratio Avg 3Y	334476.42
Current VS TTM Avg	+121.93%
Current VS 3Y Avg	-99.75%
Current VS 5Y Avg	-99.75%

Ev/Ebitda Ratio	245.43
Ev/Ebitda Ratio Avg TTM	133.55
Ev/Ebitda Ratio Avg 3Y	183129.66
Current VS TTM Avg	+83.78%
Current VS 3Y Avg	-99.87%
Current VS 5Y Avg	-99.87%

Ev/Assets Ratio	0.47
Ev/Assets Ratio Avg TTM	0.64
Ev/Assets Ratio Avg 3Y	0.70
Current VS TTM Avg	-26.38%
Current VS 3Y Avg	-32.90%
Current VS 5Y Avg	-51.00%

Ev/Sales Ratio	0.96
Ev/Sales Ratio Avg TTM	1.05
Ev/Sales Ratio Avg 3Y	2.34
Current VS TTM Avg	-8.72%
Current VS 3Y Avg	-58.93%
Current VS 5Y Avg	-67.64%

Current Ratio	2.96
Current Ratio Avg TTM	4.09
Current Ratio Avg 3Y	4.12
Current VS TTM Avg	-27.66%
Current VS 3Y Avg	-28.20%
Current VS 5Y Avg	-29.28%

Quick Ratio	2.96
Quick Ratio Avg TTM	3.94
Quick Ratio Avg 3Y	4.04
Current VS TTM Avg	-25.03%
Current VS 3Y Avg	-26.75%
Current VS 5Y Avg	-28.07%

ROIC	(16.87%)
ROIC Avg 3Y	(45.12%)
ROIC Avg 5Y	(63.78%)
Current VS 3Y Avg	+62.61%
Current VS 5Y Avg	+73.55%
Current VS 10Y Avg	+63.25%

ROA	(4.22%)
ROA Avg TTM	(5.06%)
ROA Avg 3Y	(5.26%)
Current VS TTM Avg	+16.60%
Current VS 3Y Avg	+19.73%
Current VS 5Y Avg	+48.24%

ROE	(34.04%)
ROE Avg TTM	(138.30%)
ROE Avg 3Y	(66.90%)
Current VS TTM Avg	+75.39%
Current VS 3Y Avg	+49.12%
Current VS 5Y Avg	+56.79%

Net Profit Margin	(8.70%)
Net Profit Margin Avg TTM	(58.36%)
Net Profit Margin Avg 3Y	(119.33%)
Current VS TTM Avg	+85.09%
Current VS 3Y Avg	+92.71%
Current VS 5Y Avg	+94.64%

Gross Profit Margin	71.12%
Gross Pft Margin Avg TTM	41.63%
Gross Pft Margin Avg 3Y	69.78%
Current VS TTM Avg	+70.83%
Current VS 3Y Avg	+1.92%
Current VS 5Y Avg	-2.83%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A